Li Kang Biomedical Co Ltd Cash Flow Conversion Efficiency

Latest as of March 2026: -0.004x

Li Kang Biomedical Co Ltd cash flow conversion efficiency. Based on the latest financial reports, Li Kang Biomedical Co Ltd (6242) has a cash flow conversion efficiency ratio of -0.004x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-3.17 Million ≈ $-100.00K USD) by net assets (NT$881.47 Million ≈ $27.77 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Li Kang Biomedical Co Ltd (2002–2025)

Cash flow conversion efficiency of Li Kang Biomedical Co Ltd from 2002 to 2025. This chart illustrates how Li Kang Biomedical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Li Kang Biomedical Co Ltd stock price today for real-time trading data and today's change.

Li Kang Biomedical Co Ltd Cash Flow Conversion Ratio Explained

Li Kang Biomedical Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Li Kang Biomedical Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Li Kang Biomedical Co Ltd ranked by their cash flow conversion efficiency. Also see Li Kang Biomedical Co Ltd (6242) market capitalisation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Hastings Technology Metals Ltd AU:HAS	-0.035x
Communication & System Solution Public Company Limited BK:CSS	0.010x
SJM Co Ltd KO:123700	0.023x
Eva Live Inc. Common Stock NASDAQ:GOAI	-0.231x
Shaftesbury Capital PLC LSE:SHC	0.002x
Bio-Works Technologies AB ST:BIOWKS	-0.085x
Cipherlab Co Ltd TWO:6160	-0.064x
EVZ Ltd AU:EVZ	0.060x

Annual Cash Flow Conversion Efficiency for Li Kang Biomedical Co Ltd (2002–2025)

The table below shows the annual cash flow conversion efficiency of Li Kang Biomedical Co Ltd from 2002 to 2025. Review 6242 FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	NT$871.24 Million ≈ $27.45 Million	NT$92.15 Million ≈ $2.90 Million	0.106x	+38.42%
2024-12-31	NT$855.68 Million ≈ $26.96 Million	NT$65.38 Million ≈ $2.06 Million	0.076x	-50.24%
2023-12-31	NT$630.03 Million ≈ $19.85 Million	NT$96.74 Million ≈ $3.05 Million	0.154x	-44.32%
2022-12-31	NT$570.14 Million ≈ $17.96 Million	NT$157.24 Million ≈ $4.95 Million	0.276x	+124.49%
2021-12-31	NT$492.00 Million ≈ $15.50 Million	NT$60.45 Million ≈ $1.90 Million	0.123x	-23.53%
2020-12-31	NT$508.30 Million ≈ $16.01 Million	NT$81.67 Million ≈ $2.57 Million	0.161x	-16.08%
2019-12-31	NT$483.44 Million ≈ $15.23 Million	NT$92.56 Million ≈ $2.92 Million	0.191x	-15.29%
2018-12-31	NT$466.92 Million ≈ $14.71 Million	NT$105.53 Million ≈ $3.32 Million	0.226x	-8.94%
2017-12-31	NT$445.68 Million ≈ $14.04 Million	NT$110.61 Million ≈ $3.48 Million	0.248x	-23.67%
2016-12-31	NT$340.80 Million ≈ $10.74 Million	NT$110.82 Million ≈ $3.49 Million	0.325x	+42.61%
2015-12-31	NT$280.29 Million ≈ $8.83 Million	NT$63.91 Million ≈ $2.01 Million	0.228x	+24.49%
2014-12-31	NT$227.44 Million ≈ $7.17 Million	NT$41.66 Million ≈ $1.31 Million	0.183x	-18.77%
2009-12-31	NT$128.49 Million ≈ $4.05 Million	NT$28.97 Million ≈ $912.65K	0.225x	+1252.82%
2003-12-31	NT$338.06 Million ≈ $10.65 Million	NT$5.63 Million ≈ $177.50K	0.017x	-87.37%
2002-12-31	NT$347.64 Million ≈ $10.95 Million	NT$45.87 Million ≈ $1.45 Million	0.132x	--

About Li Kang Biomedical Co Ltd

TWO:6242 Taiwan Travel Services

Market Cap

$32.97 Million

NT$1.05 Billion TWD

Market Cap Rank

#23232 Global

#1461 in Taiwan

Share Price

NT$32.90

Change (1 day)

+0.00%

52-Week Range

NT$32.90 - NT$39.80

All Time High

NT$13364.93